Académique Documents
Professionnel Documents
Culture Documents
www.datamonitor.com/healthcare
Commercial Insight: Cancer Market Top 20 Drugs Supportive Care Grows the Cancer Market
DMHC2050
Introduction
Reasons to buy
Understand market-specific drivers and predict the future performance of key
compounds
Quantify the impact of key patent expiries
Adopt knowledge to drive strategic planning for the lifecycle management
of mature products and to optimize the market penetration of new entrants
fax:
email:
hcinfo@datamonitor.com
www.datamonitor.com/healthcare
AND
LIFECYCLE
Case studies
Forecast Analysis
AstraZeneca - Market retention through patent expiry management, maturing
brand loyalty and recognized disease expertise
Early market entry
Erbitux (cetuximab)
Developed
by ImClone
andhormone-dependent
marketed by BMS in the US and Merck KGaA in Europe,
AstraZeneca (AZ) has a strong foothold
in the field
of treating
Erbitux (cetuximab)
a chimerized
monoclonal
malignancies and has maintained a particularly
prominentisrole
in the breast
cancer antibody that targets the epidermal
growth factor
receptor
(EGFR).
currently FDA and EU approved for use in
market dating back to its launch of Nolvadex
(tamoxifen)
in 1973.
TheErbitux
drugs is
first-tocombination
with enabled
irinotecan
in irinotecan-refractory
colorectal cancer patients or as
market status and robust, evidenced-based
efficacy
Nolvadex
to rapidly
monotherapy
in recurrent
metastatic
colorectal cancer for patients intolerant of
establish itself as a blockbuster therapy,
becoming
the mainstay
anti-estrogen
irinotecan-based
treatment for early- and late-stage breast
cancer. Inchemotherapy.
addition, inCountry
1998 Nolvadex
Market Assessments
became the first and only antihormonal to garner FDA approval for the prevention of
indications such as NSCLC, head and neck, and pancreatic
breast cancer in women at high risk of Although
developingadditional
the disease.
cancer could significantly add to the total sales of Erbitux from 2006 onwards, there
are a number of threats that could dampen the sales growth of the drug. Healthcare
Attempting to mitigate the impact of Nolvadex patent expiry
Figuremeans
3:
Global
oncology
sales
growth,
cost pressure in the seven major markets
that
Erbituxs
benefits
may
not 200309
justifyin its
at least
in the
European patents for Tamoxifen expired
thehigh
midcost,
1980s,
though
the US
USwhere
patentthe drug costs approximately $10,000
peratmonth,
thereby
limiting its
sales growth.
remained in place until 2002. Further,
this time
AZ obtained
a six-month
US Furthermore, there are competitive
from Abgenixs
a fully humanized EGFR monoclonal antibody, and
pediatric exclusivity extension for thethreats
treatment
of femalesABX-EGF,
with McCune-Albright
other signalhormonal
transduction
that could depress
70,000 the growth of Erbitux.
syndrome, a rare hereditary disease influencing
andinhibitors
sexual development.
Sales ($ millions)
By the time of full patent expiration in February 2003, generic erosion of Nolvadex
60,000
Erbitux is in a Phase I trial in Japan; as a result,
Datamonitor does not expect the
revenues had already commenced. However, AZ had been able to proactively and
drug to be launched in the market before 2010.
pragmatically manage the US patent expiry through the establishment of 50,000
a
confidential settlement with Barr in 1993, following the latters challenge of AZs
40,000
patent protection. Under the terms of Glivec
this agreement
AZ, or Zeneca as it was then
(imatinib)
trading, supplied Barr with tamoxifen for re-sale as a generic at a discount of 15%
30,000
Developed and marketed by Novartis Pharmaceuticals, Datamonitor considers the
less than the price of Nolvadex.
commercialization of Glivec as archetypal among
20,000MTTs. Initially approved for the
In 2002, the US market for Nolvadex and
generic
tamoxifen
was
worth
approximately
treatment of chronic myeloid leukemia (CML), Glivec targets the hyper-functioning
10,000
$500m and by the first quarter of 2003Bcr-Abl
generictyrosine
tamoxifen
salesthat
had characterizes
overtaken those
kinase
this
malignancy. Further, the drug has
of Nolvadex. In 2003, AZ reported Nolvadex
sales of
$178m,
down 63% from
2002 disease (GIST), a consequence of its
demonstrable
activity
in gastrointestinal
stromal
0
(IMS Health, April 2004). However, as activity
alreadyagainst
described,
the relationshipC-kit
between
AZ kinase.
the over-amplified
tyrosine
2002 2003 2004 2005 2006 2007 2008 2009
and Barr somewhat mitigated the formers loss in Nolvadex revenues. However,
The drug garnered global sales of $757m in the first half of 2004 (Novartis
Commercial Insight: Cancer Market Top 20 Drugs Pharmaceuticals) and while Datamonitor
DMHC2050
Source:
nitor PharmaVitae,
2004in the relatively
DATAMONITOR
feelsDatamo
that market
penetration
Datamonitor (Published 12/2004)
rare malignancies of CML and GIST isPage
close63to saturation, recent data on alternate
This report is a licensed product and is not to be photocopied
dosing schedules and potential future indications has the capacity to drive further
revenue generation. Specifically, data
High presented
unmet needat the American Society of
Hematology (ASH) conference in December 2004 (Abstract #999: Cortes J et al.,
High-dose imatinib mesylate treatment
in patients
untreated
early research for many years, successful
Although
cancerwith
haspreviously
been the focus
of intensive
chronic phase chronic myeloid leukemia)
intimated of
thatthe
patients
withespecially
CML receiving
management
disease,
for advanced tumors, is limited. Surgery
800mg of Glivec were more likely to attain
complete
cytogenetic
responses
remains
the single
treatment
optioncompared
most likely to lead to long-term survival for
to the standard dose of 400mg. The patients
drug hasdiagnosed
also recently
activity inwith pharmacotherapy often providing
withdemonstrated
early-stage disease,
Kaposis sarcoma (Koon et al., 2004)
illness responses
believed to
be
only an
briefAIDS-defining
and unpredictable
in those
patients whose disease is more
advanced at diagnosis. Because the majority of patients presenting to physicians fall
Commercial Insight: Cancer Market Top 20 Drugs into this latter category, there is a tremendous
DMHC2050 unmet need for treatments that can
Datamonitor (Published 12/2004)
52 quality of life. Datamonitor believes
provide durable clinical responses and Page
improve
This report is a licensed product and is not to be photocopied
that this high unmet need is likely to result in the continued favorable pricing of
oncology therapies.
The era of molecular-targeted treatment (MTT)
Historically, the approaches to identifying new cancer treatments have been relatively
unsophisticated, relying on crude measures of cancer cell growth or inhibition in
animals and test tubes. With the emergence of new technologies and an increased
understanding of the molecular basis for cancer evolution, the molecular changes that
Commercial Insight: Cancer Market Top 20 Drugs
Datamonitor (Published 12/2004)
DMHC2050
Page 18
Commercial Insight: Cancer Market Top 20 Drugs Supportive Care Grows the Cancer Market
DMHC2050
Table of contents
EXECUTIVE SUMMARY
- Threats
FORECAST ANALYSIS
Cytotoxics
- Taxotere (docetaxel)
- Paraplatin (carboplatin)
- Eloxatin (oxaliplatin)
- Gemzar (gemcitabine)
- Taxol (paclitaxel)
- Campto/Camptosar (irinotecan)
- Temodar/Temodal (temozolomide)
- Farmorubicin/Ellence (epirubicin)
- Xeloda (capecitabine)
- UFT (tegafur-uracil)
Antihormonals
- Lupron (leuprorelin)
- Zoladex (goserelin)
fax:
email:
hcinfo@datamonitor.com
www.datamonitor.com/healthcare
- Arimidex (anastrozole)
- Casodex (bicalutamide)
- Femara (letrozole)
- Molecular-targeted agents
- Iressa (gefitinib)
- Avastin (bevacizumab)
- Erbitux (cetuximab)
- Glivec (imatinib)
Monoclonal antibodies
- MabThera/Rituxan (rituximab)
- Herceptin (trastuzumab)
Anti-emetics
- Kytril (granisetron) and Zofran (ondansetron)
Growth factors
- Neupogen (filgrastim)
- Neulasta (pegylated filgrastim)
- Epogen (epoetin alfa)
- Erypo/Procrit (epoetin alfa)
- Recormon/Epogin (epoetin beta)
- Aranesp (darbopoetin)
Forecasts
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
6:
7:
8:
9:
10:
11:
12:
13:
14:
15:
16:
17:
18:
19:
20:
21:
22:
23:
24:
25:
26:
27:
28:
29:
30:
31:
FIGURES
Figure 1: World population aged 60 and over, 1950-2050
Figure 2: Increasing combined incidence for breast, lung,
prostate and colorectal cancer with increasing
age
Figure 3: Global oncology sales growth, 2003-2009
APPENDIX
TABLES
Table 1:
Table
Table
Table
Table
2:
3:
4:
5:
Commercial Insight: Cancer Market Top 20 Drugs Supportive Care Grows the Cancer Market
DMHC2050
Corporate Strategy
& Business Planning
Product Development
& Commercialization
Accelerate delivery
of commercial success
Expert
Analysis
Targeting &
Influencing the Market
Market &
Competitive Intelligence
Future
Forecasts
HELPING
TO GROW
YOUR
BUSINESS
Boots
Bristol-Myers Squibb
Vernalis
Cantab
Caremark International
Chiesi
Chiron
Chugai
CMC Co
Daiichi
Deutsche Morgan
Grenfell
Elan
Eli Lilly
Esteve
Flamel
Fournier
Fujisawa
Gehe
Genzyme
Gilead
Gist Brocades
GlaxoSmithKline
IBM
Immuno AG
Johnson & Johnson
Jouveinal
LEK
Lipha
Lundbeck
Merck KGaA
Merck & Co
Millennium
Pharmaceuticals
Nabi Biopharmaceuticals
Novartis
Novo Nordisk
Pfizer
Pharmachemie
Pierre Fabre
Pliva
Procter & Gamble
Ranbaxy
Recordati
Sankyo
Sanofi-Synthlabo
Schering AG
Schering-Plough
Schwarz Pharma AG
Serono
Shire Pharmaceuticals
Solvay Pharmaceuticals
Takeda
TAP Pharmaceutical
Teva
UCB
Uriach
Viatris
Wyeth
www.datamonitor.com/healthcare
www.datamonitor.com/healthcare
+44 20 7675 7016 (from Europe) or 212 686 2626 (from the US)
Product code
Price / / $ / *
__________________________________________________________________
___________________
__________________
__________________________________________________________________
___________________
__________________
__________________________________________________________________
___________________
__________________
__________________________________________________________________
___________________
__________________
__________________________________________________________________
___________________
__________________
__________________________________________________________________
___________________
__________________
__________________________________________________________________
___________________
__________________
__________________________________________________________________
___________________
__________________
* Please refer to our website www.datamonitor.com/healthcare for up-to-date prices. You can search for a product by Title or Product Code.
Name
UK
Euro
US$
Yen
I enclose a check payable to Datamonitor plc for _________ (+ p+p $30 UK / $60 rest of world)
Job Title
Department
Amex
Visa
Diners
Mastercard
Address
Card No ______________________________________________________________________
State/Province
Post Code/ZIP
Please supply purchase order number here if required by your accounts department:
Country
_____________________________________________________________________________
EU companies (except UK) must supply: VAT / BTW / MOMS / MWST / IVA / FPA number:
Tel
___________________________________________________________________________________________
Fax
Datamonitor products and services are supplied under Datamonitors standard terms and conditions,
copies of which are available on request. Payment must be received within 28 days of receipt of invoice.
I do not want to receive future mailings from Datamonitor and its related companies.
______________________________________________________________________
Occasionally, our client list is made available to other companies for carefully selected mailings.
Please check here if you do not wish to receive such mailings.
DMHC2050WEB
From Europe:
tel:
fax:
email:
hcinfo@datamonitor.com
tel:
fax:
email:
usinfo@datamonitor.com
tel:
fax:
email:
apinfo@datamonitor.com